To explore the maximum tolerated dose (MTD) of pomalidomide in combination with obinutuzumab in patients with relapsed/refractory indolent lymphomas (including follicular lymphoma, marginal zone lymphoma, and chronic lymphocytic leukemia/small lymphocytic lymphoma) treated with the pomalidomide plus obinutuzumab combination regimen, and to determine the recommended phase II dose (RP2D); concurrently evaluating the efficacy and safety of pomalidomide combined with obinutuzumab in patients with relapsed/refractory indolent lymphomas.
Age ≥18 years old, regardless of gender;
Histopathologically confirmed CD20+ indolent lymphoma (FL, MZL, or SLL), WHO grade 1-3a;.
Relapsed or refractory disease after at least one prior line of therapy;.
ECOG-PS 0-2;
Any other type of lymphoma, including Burkitt lymphoma;
The investigator confirms that the patient may progress to aggressive lymphoma.
Patients with contraindications or allergies to the investigational drug.
History of VTE or cerebral infarction prior to treatment;.